Walbert Timothy P 4

What Happened
Timothy P. Walbert, a director of Odyssey Therapeutics (ODTX), was granted a derivative award for 27,393 shares on May 7, 2026. The filing reports an acquisition price of $0.00 (no cash paid on grant) and lists the instrument as a derivative (an option). The option is scheduled to vest in full on May 7, 2027, subject to his continued service.

Key Details

• Transaction date: May 7, 2026; Form 4 filed May 11, 2026 (timely within reporting window).
• Transaction type/code: Award/Grant (A), derivative security (option).
• Amount: 27,393 shares; reported acquisition price $0.00; reported value $0.
• Vesting: Option will vest in full on May 7, 2027, subject to continued service (footnote).
• Shares owned after transaction: Not specified in the provided filing details.
• No indication of a 10b5-1 plan, sale, or tax-withholding reported in this filing.

Context
This was a compensation-related equity award to a board member, not an open-market purchase or sale. Such option grants are commonly used for director compensation and do not reflect an immediate cash investment or a decision to sell shares. The award will only translate to actual stock ownership if and when the option vests and is exercised (exercise price and post-vesting details not disclosed in this Form 4).